Art. -Nr.: HY-108610

Copy Link Print Information

(R)-Edelfosine

(Synonyms: (R)-ET-18-OCH3)

Kundenbewertung

Based on 1 Customer Validation

(R)-Edelfosine ((R)-ET-18-OCH3) is a ether lipid analog with anti-HIV and antineoplastic activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.9%
CAS. Nr.: 77286-66-9
Formel: C₂₇H₅₈NO₆P
Molecular Weight:523.73

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

(R)-Edelfosine Chemical Structure

CAS. Nr.: 77286-66-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

(R)-Edelfosine ((R)-ET-18-OCH3) is a ether lipid analog with anti-HIV and antineoplastic activity^[1].

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	5.05 μM Compound: 1	Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs	[PMID: 8765506]
AMML	IC₅₀	3.3 μM Compound: 1	Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia) Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia)	[PMID: 3761322]
CML/BC	IC₅₀	1.5 μM Compound: 1	Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis) Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis)	[PMID: 3761322]
Glioblastoma cell line	IC₅₀	20 μM Compound: 1	Compound was tested for the inhibition of glioblastoma Compound was tested for the inhibition of glioblastoma	[PMID: 3761322]
HL-60	IC₅₀	2.5 μM Compound: 1	Compound was tested for the inhibition of human HL60 Leukemia Compound was tested for the inhibition of human HL60 Leukemia	[PMID: 3761322]
HT-29	GI₅₀	2.2 μM Compound: 1	Inhibitor activity against HT-29 (Human colon carcinoma)cell line with varying concentration of the drug for 72 hrs Inhibitor activity against HT-29 (Human colon carcinoma)cell line with varying concentration of the drug for 72 hrs	[PMID: 8765506]
L1210	GI₅₀	10.99 μM Compound: 1	Inhibitor activity against L1210/vmdr (transfected with a plasmid containing mdr1) cell line with varying concentration of the drug for 72 hrs Inhibitor activity against L1210/vmdr (transfected with a plasmid containing mdr1) cell line with varying concentration of the drug for 72 hrs	[PMID: 8765506]
L1210	GI₅₀	3.32 μM Compound: 1	Inhibitor activity against L1210 (murine leukemia )cell line with varying concentration of the drug for 72 hrs Inhibitor activity against L1210 (murine leukemia )cell line with varying concentration of the drug for 72 hrs	[PMID: 8765506]
Lewis lung carcinoma cell line	GI₅₀	30.24 μM Compound: 1	Inhibitor activity against Lewis lung (murine lung carcinoma)cell line with varying concentration of the drug for 72 hrs Inhibitor activity against Lewis lung (murine lung carcinoma)cell line with varying concentration of the drug for 72 hrs	[PMID: 8765506]
MCF7	GI₅₀	30.35 μM Compound: 1	Inhibitor activity against MCF-7/Adr (Human colon carcinoma)cell line with varying concentration of the drug for 72 hrs Inhibitor activity against MCF-7/Adr (Human colon carcinoma)cell line with varying concentration of the drug for 72 hrs	[PMID: 8765506]
MCF7	GI₅₀	9.66 μM Compound: 1	Inhibitor activity against MCF-7(Human breast carcinoma)cell line with varying concentration of the drug for 72 hrs Inhibitor activity against MCF-7(Human breast carcinoma)cell line with varying concentration of the drug for 72 hrs	[PMID: 8765506]
NSCLC	IC₅₀	21 μM Compound: 1	Compound was tested for the inhibition of non- small cell lung cancer Compound was tested for the inhibition of non- small cell lung cancer	[PMID: 3761322]
P388	GI₅₀	4.33 μM Compound: 1	Inhibitor activity against P388 (murine leukemia )cell line with varying concentration of the drug for 72 hrs Inhibitor activity against P388 (murine leukemia )cell line with varying concentration of the drug for 72 hrs	[PMID: 8765506]
P388	GI₅₀	6.39 μM Compound: 1	Inhibitor activity against P388/Adr (murine leukemia )cell line with varying concentration of the drug for 72 hrs Inhibitor activity against P388/Adr (murine leukemia )cell line with varying concentration of the drug for 72 hrs	[PMID: 8765506]
RBL-2H3	IC₅₀	7.1 μM Compound: 1	Inhibition of rat RBL2H3 cell granulation assessed as reduction of beta hexasaminidase release Inhibition of rat RBL2H3 cell granulation assessed as reduction of beta hexasaminidase release	[PMID: 20153565]
Small cell lung cancer cell line	IC₅₀	24 μM Compound: 1	Compound was tested for the inhibition of small cell lung cancer Compound was tested for the inhibition of small cell lung cancer	[PMID: 3761322]

Chemical Information

CAS. Nr. 77286-66-9
Appearance Solid
Molecular Weight 523.73
Formel C₂₇H₅₈NO₆P
Color White to off-white
SMILES

CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP(OCC[N+](C)(C)C)([O-])=O
Synonyms

(R)-ET-18-OCH3
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 10 mg/mL (19.09 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9094 mL

9.5469 mL

19.0938 mL

5 mM

0.3819 mL

1.9094 mL

3.8188 mL

10 mM

0.1909 mL

0.9547 mL

1.9094 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (262 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Xie X, et al. Interdigitation of bilayers from ether lipid analogs: (R)-PAF, (R)-Lyso-PAF and the antineoplastic (R)-ET-18-OMe. Biochim Biophys Acta. 1996 Aug 14;1283(1):111-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	1.9094 mL	9.5469 mL	19.0938 mL	47.7345 mL
	5 mM	0.3819 mL	1.9094 mL	3.8188 mL	9.5469 mL
	10 mM	0.1909 mL	0.9547 mL	1.9094 mL	4.7735 mL
	15 mM	0.1273 mL	0.6365 mL	1.2729 mL	3.1823 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

(R)-Edelfosine

Anti-Infection Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Covalent Screening Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

(R)-Edelfosine

Anti-Infection Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Covalent Screening Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

(R)-Edelfosine Related Classifications

HY-108610 Related Classifications